Skip to main content

Table 1 Association of C12orf59 expression with patient’s clinicopathological features in GC

From: RETRACTED ARTICLE: A positive feedback loop consisting of C12orf59/NF-κB/CDH11 promotes gastric cancer invasion and metastasis

Variables

Case

Training cohort

P-value

Case

Validation cohort

P-value

Low expression

High expression

Low expression

High expression

Age

 

102

68

  

79

53

 

≤60a

100

65 (50.9%)

35 (49.1%)

 

78

51 (54.5%)

27 (45.5%)

 

>60

70

37 (58.1%)

33 (41.9%)

0.112

54

28 (53.5%)

26 (46.5%)

0.119

Gender

 Male

109

64 (50.0%)

45 (50.0%)

 

88

51 (50.0%)

37 (50.0%)

 

 Female

61

38 (63.3%)

23 (36.7%)

0.648

44

28 (63.3%)

16 (36.7%)

0.53

Tumor grade

 G1

56

39 (42.1%)

17 (57.8%)

 

38

23 (65.8%)

15 (34.2%)

 

 G2 + 3

114

63 (61.7%)

51 (38.3%)

0.072

94

56 (46.7%)

38 (53.3%)

0.92

Tumor size(cm)

 ≤ 5b

91

59 (51.0%)

32 (49.0%)

 

97

62 (53.1%)

35 (46.9%)

 

 >5

79

43 (57.1%)

36 (42.9%)

0.167

35

17 (55.1%)

18 (44.9%)

0.112

T status

 T1/2

37

25 (54.2%)

12 (45.8%)

 

44

31 (50.0%)

13 (50.0%)

 

 T3/4

133

77 (54.1%)

56 (45.9%)

0.288

88

48 (55.4%)

40 (44.6%)

0.079

N status

 N0

58

43 (34.5%)

15 (65.5%)

 

61

43 (72.4%)

18 (27.6%)

 

 N1/2

112

59 (62.3%)

53 (37.7%)

0.007*

71

36 (46.4%)

35 (53.6%)

0.021*

Clinical stage

 I + II

69

50 (37.8%)

19 (62.2%)

 

70

49 (67.6%)

21 (32.4%)

 

 III

101

52 (63.9%)

49 (36.1%)

0.006*

62

30 (45.9%)

32 (54.1%)

0.011*

  1. a Mean age. b Mean tumor size. *Statistically significant difference